The Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Pain in Laparoscopic Cholecystectomy

• Status: Completed
• Trial end date: 2020-08-06
• Target enrollment: 0
• Participant gender: All

Summary

Injection of intraperitoneal bupivacaine revealed an analgesic effect whether injected alone or in combination with other adjuvants, which increase duration of analgesia and decrease the dose of administered bupivacaine thus minimizing its side effects e.g. Opioids, Corticosteroids and Magnesium sulphate.

Neostigmine, a cholinesterase inhibitor that produces muscarinic receptor-mediated analgesia, increased postoperative analgesia when combined with local anaesthetics. Peripheral afferent nerve fibres contain muscarinic receptors, these could be a good target for pain suppression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kasr El Aini Hospital
• Treatments: Bupivacaine; Neostigmine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• • American Society of Anaesthesiologist (ASA) I-II.

• Age 18 - 60 years.

• Elective laparoscopic cholecystectomy.

• Body Mass Index (BMI) <35 (kg/m2).

Exclusion Criteria:

• • Anaphylaxis to local anaesthetics.

• Anaphylaxis to Neostigmine.

• American Society of Anaesthesiologist (ASA) III-IV.

• Chronic pain diseases.

• Acute cholecystitis.

• Psychological or nervous system diseases